Three Part Question
In [patients with life threatening haematuria] does [tranexamic acid] [improve outcomes]
Clinical Scenario
A 70yr old man is rushed into resus with a BP of 60/30. He has been passing blood and clots in the urine for the last 24 hours. As you commence fluid resuscitation you wonder whether tranexamic acid may have a role in his manageemnt
Search Strategy
Medline using NHS evidence date of searching 20 November 2014: [exp tranexamic acid/OR tranexamic AND acid.ti,ab OR txa.ti,ab] AND [exp hematuria/ OR haematuria. ti, ab].
Embase using NHS evidence SAFETY SEARCH: [*tranexamic acid/] AND [*hematuria/OR haematuria. ti, ab].
The Cochrane Library Issue 11 of 12, November 2014: MeSH descriptor: [Tranexamic Acid] explode all trees AND MeSH descriptor: [Hematuria] explode all trees.
Search Outcome
Sixteen papers were found, of which four provided the best evidence to answer the question
Relevant Paper(s)
Author, date and country |
Patient group |
Study type (level of evidence) |
Outcomes |
Key results |
Study Weaknesses |
Vujkovac B.,Sabovic M. 2006 Slovenia | One patient with autosomal dominant polycystic kidney disease (ADPKD) | Case report | Nephrectomy | Bilateral Nephrectomies avoided | Case report. |
Thromboembolism | Ureters obstructed by clots requiring J stents |
Mortality | Patient survived |
Peces R et al 2012 Spain | 8 patients with autosomal dominant polycystic kidney disease (ADPKD) | Prospective observational study | Cessation of haematuria | Stopped within 2-5 days in all patients | Only 8 patients. All patients had ADPKD. |
Renal function | Remained stable |
Haemoglobin | Remained stable |
Mortality | All patients survived |
Thromboembolism | No cases of thromboemblism |
Alameel T, West M 2011 Canada | One patient with autosomal dominant polycyctic kidney disease (ADPKD) with recurrent episodes of life threatening haematuria. | Case report | Haematuria | Stopped within 24-36hrs | Case report. |
Renal function | Improved to baseline |
Thromboembolism | No incidence of thromboembolism |
Mortality | Patient survived |
Davies N et al 2010 Ireland | Female patient with sickle cell anaemia and haematuria requiring blood transfusion | Case report | Haematuria | Stopped within 4 days of treatment | Case report. |
Haemoglobin | Remained stable |
Mortality | Patient survived |
Thromboembolism | No incidence of thromboembolism |
Comment(s)
The evidence for the use of tranexamic acid in life-threatening haematuria is weak and predominantly in patients with autosomal-dominant polycystic kidney disease. The case reports do suggest a benefit, but larger studies are needed to prove this benefit and exclude the increased risk of thromboembolic complications.
Clinical Bottom Line
The evidence is limited, but there may be a role for tranexamic acid in life-threatening haematuria, particularly in patients with autosomal-dominant polycystic kidney disease.
References
- Vujkovac B.,Sabovic M. A successful treatment of life-threatening bleeding from polycystic kidneys with antifibrinolytic agent tranexamic acid. Blood Coagul Fibrinolysis 2006;17:589–91.
- Peces R, Aguilar A, Vega C, et al. Medical therapy with tranexamic acid in autosomal dominant polycystic kidney disease patients with severe haematuria. Nefrologia 2012;32:160–5.
- AlAmeel T, West M. Tranexamic Acid Treatment of Life-Threatening Hematuria in Polycystic Kidney Disease. Int J Nephrol. 2011;2011:203579.
- Davies NF, McGuire BB, Lawlor L, et al. Oral tranexamic acid as a novel treatment option for persistent haematuria in patients with sickle cell disease. Ann Hematol 2010;89:1179–80.